Tyson Lee

832 total citations
10 papers, 670 citations indexed

About

Tyson Lee is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Tyson Lee has authored 10 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Genetics and 2 papers in Molecular Biology. Recurrent topics in Tyson Lee's work include Erythropoietin and Anemia Treatment (7 papers), Hemoglobinopathies and Related Disorders (6 papers) and Acute Myeloid Leukemia Research (3 papers). Tyson Lee is often cited by papers focused on Erythropoietin and Anemia Treatment (7 papers), Hemoglobinopathies and Related Disorders (6 papers) and Acute Myeloid Leukemia Research (3 papers). Tyson Lee collaborates with scholars based in United States, Australia and Israel. Tyson Lee's co-authors include Thomas B. Neff, Robert Provenzano, Robert Leong, Anatole Besarab, Kin-Hung P. Yu, Stefan Hemmerich, Stephen J. Klaus, Joachim Hertel, Raja I. Zabaneh and Dongxia Li and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Kidney Diseases.

In The Last Decade

Tyson Lee

10 papers receiving 658 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tyson Lee United States	7	313	207	195	173	149	10	670
Kin-Hung P. Yu United States	8	605 1.9×	304 1.5×	246 1.3×	171 1.0×	259 1.7×	19	1.1k
Robert Leong United States	9	683 2.2×	322 1.6×	271 1.4×	130 0.8×	293 2.0×	14	954
Olena Davidoff United States	9	414 1.3×	369 1.8×	107 0.5×	288 1.7×	217 1.5×	13	879
Steven Zeig United States	11	637 2.0×	146 0.7×	751 3.9×	58 0.3×	275 1.8×	23	1.2k
G. Brant Walton United States	11	365 1.2×	62 0.3×	54 0.3×	281 1.6×	108 0.7×	12	818
ST Koury United States	7	750 2.4×	180 0.9×	70 0.4×	257 1.5×	280 1.9×	8	1.1k
MJ Koury United States	9	761 2.4×	183 0.9×	71 0.4×	291 1.7×	287 1.9×	13	1.1k
Nariaki Asada Japan	9	99 0.3×	56 0.3×	159 0.8×	207 1.2×	61 0.4×	17	471
Udaya Valluri United States	7	228 0.7×	60 0.3×	95 0.5×	12 0.1×	90 0.6×	15	380
Yabing Chen United States	10	62 0.2×	171 0.8×	45 0.2×	231 1.3×	25 0.2×	18	548

Countries citing papers authored by Tyson Lee

Since Specialization

Citations

This map shows the geographic impact of Tyson Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tyson Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tyson Lee more than expected).

Fields of papers citing papers by Tyson Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tyson Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tyson Lee. The network helps show where Tyson Lee may publish in the future.

Co-authorship network of co-authors of Tyson Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Tyson Lee. A scholar is included among the top collaborators of Tyson Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tyson Lee. Tyson Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Lü, Shun, Jiong Wu, Jiang Jin, et al.. (2024). Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. Journal of Clinical Oncology. 43(2). 143–153. 5 indexed citations

Mittelman, Moshe, David H. Henry, John A. Glaspy, et al.. (2024). Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial. American Journal of Hematology. 99(9). 1778–1789. 7 indexed citations

Mittelman, Moshe, David H. Henry, John A. Glaspy, et al.. (2023). Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study. Blood. 142(Supplement 1). 195–195. 3 indexed citations

Glaspy, John A., et al.. (2023). Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies. American Journal of Hematology. 98(5). 703–711. 11 indexed citations

Glaspy, John A., Nashat Gabrail, Gopal Saha, et al.. (2022). Open-label, phase 2 study of roxadustat for treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.. Journal of Clinical Oncology. 40(16_suppl). 12085–12085. 1 indexed citations

Provenzano, Robert, Anatole Besarab, Chao Sun, et al.. (2016). Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Clinical Journal of the American Society of Nephrology. 11(6). 982–991. 223 indexed citations

Besarab, Anatole, Robert Provenzano, Joachim Hertel, et al.. (2015). Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation. 30(10). 1665–1673. 232 indexed citations

Picozzi, Vincent J., J. Marc Pipas, Albert C. Koong, et al.. (2014). FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 32(15_suppl). 4138–4138. 10 indexed citations

Provenzano, Robert, David A. Goodkin, Stephen J. Klaus, et al.. (2011). 253 Evaluation of FG-4592, a Novel Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, to Treat Anemia in Hemodialysis Patients. American Journal of Kidney Diseases. 57(4). B80–B80. 7 indexed citations

10.

Adler, Sharon G., Sherwyn Schwartz, Mark E. Williams, et al.. (2010). Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria. Clinical Journal of the American Society of Nephrology. 5(8). 1420–1428. 171 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact